PHC revenues down 8% in 2014
The US-based, UK-listed bioproducts company, Plant Health Care (PHC - Raleigh, North Carolina), recorded a 7.7% decline in revenues to $6.9 million in 2014. The company attributes the fall to a reduction in licensing and milestone payments. Sales of the disease resistance activator, Harpin αβ, and the drought resistance product, Myconate, rose by 44% to $3.6 million. These proprietary products accounted for about 53% of total revenues compared with 34% in 2013, the remainder coming from third-party product sales, mainly in Mexico.